ReviewFrontiers in immunology2026
Serum amyloid A in the oral microenvironment: implications for inflammation, host-microbe interactions, and disease monitoring.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To summarize current evidence regarding the role of serum amyloid A (SAA) in the oral microenvironment, with particular focus on its involvement in oral inflammation, host-microbe interactions, biofilm-associated chronic inflammation, and its potential utility as a diagnostic biomarker. Methods: Relevant literature regarding SAA in oral inflammation, host-microbe interactions, oral carcinogenesis, and salivary diagnostics was reviewed and synthesized. Particular emphasis was placed on studies investigating oral pathogens, inflammatory signaling pathways, biofilm-associated inflammation, salivary diagnostics, and veterinary applications of salivary SAA monitoring. Results: Accumulating evidence indicates that SAA is not only a classical acute-phase protein but also an active regulator of inflammatory responses. In the oral cavity, pathogenic microorganisms and persistent biofilm-associated stimulation can induce local and systemic SAA expression through innate immune signaling pathways, including TLR2/TLR4 and NF-κB signaling. SAA contributes to neutrophil recruitment, macrophage activation, cytokine amplification, and maintenance of chronic inflammatory microenvironments. Emerging studies further suggest that SAA may participate in biofilm-associated inflammatory persistence and may contribute to tissue remodeling and disease progression. In addition, SAA can be detected in saliva and inflammatory oral fluids, highlighting its potential as a non-invasive biomarker for disease monitoring. Veterinary studies investigating salivary SAA further support the feasibility of continuous and minimally invasive inflammatory monitoring. Conclusions: SAA represents an important molecular link between oral microbial dysbiosis, chronic inflammation, and disease progression within the oral microenvironment. Beyond its role as a systemic inflammatory marker, SAA actively participates in immune regulation and host-microbe interactions. Salivary SAA monitoring may provide a promising non-invasive approach for longitudinal assessment of oral inflammatory diseases and related pathological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.